Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s key product candidate, Melphalan Hydrochloride (Melphalan/HDS) for Injection for use with the Delcath Hepatic Delivery System is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Melphalan/HDS is approved for sale under the trade name Delcath CHEMOSAT ® Hepatic Delivery System for Melphalan. Co.'s primary research focus is on ocular melanoma liver metastases and intrahepatic cholangiocarcinoma as well as certain other cancers that are metastatic to the liver. The DCTH stock yearly return is shown above.
The yearly return on the DCTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DCTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|